---
layout: default
title: Abaloparatide
parent: 僅模型預測 (L5)
nav_order: 11
evidence_level: L5
indication_count: 4
---

# Abaloparatide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **4** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ABALOPARATIDE: Preliminary Evaluation — Awaiting Prediction Data

## One-Sentence Summary

Abaloparatide (DrugBank: DB05084) is a synthetic peptide analog of parathyroid hormone-related protein (PTHrP), known internationally for the treatment of postmenopausal osteoporosis at high risk of fracture. The TxGNN model has **not yet generated any predicted new indications** for this drug, and the evidence pack contains significant data gaps in mechanism of action and safety information. This report serves as a **baseline record** pending completion of prediction and data enrichment.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in current evidence pack (known externally: postmenopausal osteoporosis) |
| Predicted New Indication | — (No prediction available) |
| TxGNN Prediction Score | — |
| Evidence Level | **L5** (No prediction or supporting studies) |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on publicly known information, abaloparatide is a synthetic analog of human parathyroid hormone-related protein (PTHrP(1-34)). It acts as a selective activator of the PTH1 receptor signaling pathway, preferentially stimulating the RG conformation of the receptor, which promotes bone formation over bone resorption. It is approved in the United States (brand name: Tymlos) for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

**No TxGNN prediction has been generated for this drug.** The `predicted_indications` array is empty, meaning the model either has not yet processed this compound or did not identify candidate indications above the confidence threshold. Without a predicted new indication, no mechanism-based plausibility analysis can be conducted at this time.

To move forward, the following data enrichment steps are required:
1. Complete the TxGNN prediction pipeline for ABALOPARATIDE
2. Retrieve and populate the mechanism of action (MOA) from DrugBank API
3. Obtain TFDA package insert warnings and contraindications

---

## Clinical Trial Evidence

Currently no predicted indication is available; therefore, no targeted clinical trial search has been performed.

---

## Literature Evidence

Currently no predicted indication is available; therefore, no targeted literature search has been performed.

---

## Taiwan Market Information

ABALOPARATIDE is **not currently marketed in Taiwan**. No TFDA marketing authorizations were found (query date: 2026-03-29). There are zero registered licenses, and no dosage forms are available through local channels.

---

## Safety Considerations

> Please refer to the package insert for safety information.
>
> Note: TFDA package insert warnings/contraindications and drug-drug interaction data are currently unavailable for this drug in Taiwan. The DDI query returned no results. These represent **blocking data gaps** that must be resolved before any safety assessment can proceed.

---

## Data Gaps Summary

The following critical data gaps were identified in this evidence pack:

| Gap ID | Category | Item | Severity | Remediation |
|--------|----------|------|----------|-------------|
| DG001 | Drug Level | TFDA Package Insert Warnings/Contraindications | **Blocking** | Download and parse package insert PDF from TFDA website |
| DG002 | Drug Level | Mechanism of Action (MOA) | **High** | Query DrugBank API |
| — | Prediction | TxGNN Predicted Indications | **Blocking** | Run TxGNN prediction pipeline |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN predicted indications are available for ABALOPARATIDE, and critical data gaps remain in mechanism of action and safety information. Without a predicted new indication, evidence-level assessment and risk-benefit analysis cannot be performed. The drug is also not marketed in Taiwan, adding regulatory complexity to any potential repurposing effort.

**To proceed, the following is needed:**
- Run the TxGNN prediction model for ABALOPARATIDE to generate candidate new indications
- Retrieve detailed mechanism of action (MOA) data from DrugBank API (DG002)
- Obtain TFDA package insert for safety warnings and contraindications (DG001), or source equivalent regulatory safety data from FDA/EMA if Taiwan labeling is unavailable
- If predictions are generated, conduct targeted clinical trial and literature searches for the top-ranked indication
- Reassess evidence level and decision once the above gaps are filled
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

